Published online Mar 9, 2016. doi: 10.5497/wjp.v5.i1.15
Peer-review started: September 1, 2015
First decision: November 24, 2015
Revised: December 11, 2015
Accepted: January 5, 2016
Article in press: January 7, 2016
Published online: March 9, 2016
Core tip: This article serves to discuss the changing role of non-selective beta-blockers in liver disease and portal hypertension. For many years non-selective beta-blockers have been at the forefront in reducing portal hypertensive complications such as variceal haemorrhage, however recent data has questioned their role in advanced liver disease. This article reviews their role in portal hypertension, discusses recent advances in the field and reviews the controversy recently generated regarding their role in advanced liver disease.